ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Should Transcatheter Aortic Valve Replacement Be Performed in Nonagenarians?: Insights From the STS/ACC TVT Registry

Tuesday, March 22, 2016

Submitted by

Ruben Osnabrugge

Source

Source Name: J Am Coll Cardiol

Source URL: http://content.onlinejacc.org/article.aspx?articleID=2505138

Author(s)

Mani Arsalan; Molly Szerlip; Sreekanth Vemulapalli; Elizabeth M. Holper; Suzanne V. Arnold; Zhuokai Li; Michael J. DiMaio; John S. Rumsfeld; David L. Brown; Michael J. Mack

In this study the STS/ACC Transcatheter Valve Therapy registry was used to compare TAVI in nonogenarians versus TAVI in patients <90 years old. In total 3,773 (15.7%) of the patients were >90 years old. Mortality at 30 days and 1-year was significantly higher for nonogenarians (8.8% vs. 5.9%, p<0.001 and 24.8% vs. 22.0%, p=0.001, respectively). With regard to quality of life, nonogenarians did worse at 30 days than the younger patients, while at 1 year there was no significant difference. Although the study had to exclude 35% of the long-term follow-up and there were many missing quality of life data, the authors conclude that this large study confirms the safety and efficacy of TAVR in nonogenarians.